The FDA has lifted a temporary clinical hold on EryDel’s IND for its rare disease drug-device product, boding well for California biotech Quince Therapeutics, which is set to acquire EryDel.
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia